- ProSomnus Contributes Two Scientific Abstracts for Presentation at SLEEP 2024, A Joint Meeting of the American Academy of Sleep Medicine and the Sleep Research Society
- ProSomnus Announces Strong First Quarter 2024 Revenue Growth
- ProSomnus Contributes Two Scientific Abstracts Accepted for Presentation at the 2024 American Academy of Dental Sleep Medicine Annual Meeting
- Four Independent Scientific Abstracts at the American Academy of Dental Sleep Medicine Annual Meeting Feature ProSomnus Intraoral Medical Devices
- ProSomnus Sleep Technologies Takes Strategic Action to Position Company for Long-Term Success
- ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results
- ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call
- ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
- ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024
- ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
More ▼
Key statistics
On Friday, Prosomnus Inc (OSAPQ:PKC) closed at 0.03, 275.00% above the 52 week low of 0.008 set on May 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.039 |
---|---|
High | 0.039 |
Low | 0.026 |
Bid | -- |
Offer | -- |
Previous close | 0.0275 |
Average volume | 10.80k |
---|---|
Shares outstanding | 17.39m |
Free float | 15.29m |
P/E (TTM) | -- |
Market cap | 487.03k USD |
EPS (TTM) | -1.15 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 20:35 BST.
More ▼